In immunotherapy studies for rectal colon cancer, IL-17A was shown to increase PD-L1 expression via the p65/Nrf2/miR-15b-5p axis, helping tumor cells to undergo immune escape, and blocking IL-17A improved the efficacy of anti-PD-L1 [23]. The gene discussed is NFE2L2; the disease is neoplasm.